Finoriq research workspace

X4 Pharmaceuticals, Inc (XFOR) Historical Metrics

X4 Pharmaceuticals, Inc offers XOLREMDI, an orally small-molecule selective antagonist of chemokine. Review XFOR valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Company

X4 Pharmaceuticals, Inc (XFOR)

Ticker

XFOR

Market Cap

$346.6M

Latest Price

$3.675

Industry

Biotech & Pharma

Open insider transactions

X4 Pharmaceuticals, Inc (XFOR) Current Valuation Metrics

Static valuation preview for X4 Pharmaceuticals, Inc (XFOR). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.